Morgan Stanley lowered the firm’s price target on GoodRx (GDRX) to $6 from $7 and keeps an Equal Weight rating on the shares. Diversified Managed Care “woefully underperformed” in 2024 and while uncertainty is pressuring sentiment, the firm sees “opportunities in a friendlier policy backdrop,” the analyst tells investors in a 2025 outlook note on the healthcare services group. Among Healthcare Technology and Providers, the firm remains selective due to mixed demand and policy uncertainties, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX:
Questions or Comments about the article? Write to editor@tipranks.com